Performance analysis of Connect Biopharma (CNTB)
Annual Return
Since Sep 3, 2025, CNTB has had an average annual return of +12.67%, underperforming the benchmark SPY, which returned +20.15% annual.
| 2026 | 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.63% | +41.71% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.90% | +2.92% | +6.07% | -5.73% | +0.81% | -4.42% | -7.14% | -21.63% | |||||
| 2025 | -24.12% | +13.24% | +64.33% | +0.35% | +41.71% |
Drawdown analysis of Connect Biopharma (CNTB)
The maximum drawdown for the CNTB was -46.07%, occurring on Jun 16, 2026. This drawdown has not yet recovered.
The current CNTB drawdown is -40.11%.
Since Sep 3, 2025 CNTB has experienced the following drawdowns:
- 40% or more: 1 time
- 30% or more: 3 times
- 20% or more: 3 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -46.07% | Mar 26, 2026 | 56 | Jun 16, 2026 | Ongoing | Ongoing | Ongoing |
| -33.81% | Sep 3, 2025 | 18 | Sep 29, 2025 | 34 | Nov 14, 2025 | 52 |
| -32.70% | Nov 19, 2025 | 35 | Jan 12, 2026 | 50 | Mar 25, 2026 | 85 |